Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 195.00
Bid: 194.00
Ask: 196.00
Change: 6.00 (3.17%)
Spread: 2.00 (1.03%)
Open: 186.00
High: 197.00
Low: 194.60
Yest. Close: 189.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Avacta signs global distribution deal with Abcam

Tue, 6th Apr 2021 11:03

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.
The AIM-traded firm said its Affimer reagents could be used in a high-performance ELISA laboratory test to detect the SARS-CoV-2 spike protein, with "high sensitivity and excellent specificity" for the spike protein of the original strain of the coronavirus, and other dominant variants such as the B117, or 'Kent', strain, and D614G.

It described Abcam as a leading supplier of biological reagents and kits, used in a range of fields including drug discovery, diagnostics and basic research.

Under the worldwide, non-exclusive distribution agreement, Avacta said Abcam would enable the global research community to access its SARS-CoV-2 spike protein Affimer research reagents through its online catalogue.

That would allow scientists globally to perform the ELISA test in their own laboratories, and support the global fight against the pandemic.

"We are delighted that we have established a global route to market for the SARS-CoV-2 spike protein Affimer® reagents through Abcam's dedicated global commercialisation infrastructure," said chief executive officer Dr Alastair Smith.

"As far as we are aware, our spike protein ELISA test is the most sensitive test of its kind and, in Abcam, we have a world-leading partner capable of maximising the commercial potential of the Affimer reagents by making them globally available to scientists who are researching into the SARS-CoV-2 coronavirus."

At 1946 BST, shares in Avacta Group were up 6.44% at 248p, while those in Abcam were 0.57% firmer at 1,418p.

More News

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

AIM WINNERS & LOSERS: Mercantile Ports jumps on pact; Avacta recovers

23 Jun 21 10:28

IN BRIEF: Avacta signs distribution deal for its Covid test

IN BRIEF: Avacta signs distribution deal for its Covid test

21 Jun 21 19:24

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

21 Jun 21 16:11

Avacta enters non-exclusive distribution deal for Covid-19 test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has entered into a non-exclusive distribution agreement with life science products company Calibre Scientific, it announced on Monday, for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use in the UK and the European Economic Area (EEA).

21 Jun 21 08:37

Avacta to sell rapid Covid-19 test in EU following registration

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.

11 Jun 21 12:27

Avacta Covid lateral flow test gets regulatory green light in EU

Avacta Covid lateral flow test gets regulatory green light in EU

11 Jun 21 11:40

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

IN BRIEF: Avacta Covid lateral flow test gets regulatory green light

7 Jun 21 11:31

Avacta gets MHRA registration for rapid Covid-19 test

(Sharecast News) - Diagnostics and cancer therapy developer Avacta Group announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test for Covid-19, allowing it to place the product on the market in the UK for professional use.

7 Jun 21 10:11

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

1 Jun 21 20:24

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

1 Jun 21 11:16

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

28 May 21 11:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

28 May 21 07:29

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

10 May 21 11:13

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

22 Apr 21 12:17

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

20 Apr 21 15:18

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.